CN118679259A - 抑制LPA（Apo(a)）蛋白表达的组合物和方法 - Google Patents

抑制LPA（Apo(a)）蛋白表达的组合物和方法 Download PDF

Info

Publication number
CN118679259A
CN118679259A CN202380021107.1A CN202380021107A CN118679259A CN 118679259 A CN118679259 A CN 118679259A CN 202380021107 A CN202380021107 A CN 202380021107A CN 118679259 A CN118679259 A CN 118679259A
Authority
CN
China
Prior art keywords
lpa
subject
dsrna
dsrna agent
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380021107.1A
Other languages
English (en)
Chinese (zh)
Inventor
舒东旭
邵鹏程
夏时伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Bowang Pharmaceutical Co ltd
Original Assignee
Shanghai Bowang Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Bowang Pharmaceutical Co ltd filed Critical Shanghai Bowang Pharmaceutical Co ltd
Publication of CN118679259A publication Critical patent/CN118679259A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380021107.1A 2022-01-24 2023-01-23 抑制LPA（Apo(a)）蛋白表达的组合物和方法 Pending CN118679259A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022073415 2022-01-24
CNPCT/CN2022/073415 2022-01-24
PCT/CN2023/073456 WO2023138689A1 (zh) 2022-01-24 2023-01-23 抑制LPA(Apo(a))蛋白表达的组合物和方法

Publications (1)

Publication Number Publication Date
CN118679259A true CN118679259A (zh) 2024-09-20

Family

ID=87347910

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380021107.1A Pending CN118679259A (zh) 2022-01-24 2023-01-23 抑制LPA（Apo(a)）蛋白表达的组合物和方法

Country Status (16)

Country Link
US (2) US20250297250A1 (enExample)
EP (1) EP4471144A4 (enExample)
JP (2) JP7833044B2 (enExample)
KR (1) KR20240135657A (enExample)
CN (1) CN118679259A (enExample)
AU (1) AU2023210010A1 (enExample)
CA (1) CA3248387A1 (enExample)
CL (1) CL2024002168A1 (enExample)
CO (1) CO2024009492A2 (enExample)
DO (1) DOP2024000141A (enExample)
IL (1) IL314060A (enExample)
JO (1) JOP20240159A1 (enExample)
MX (1) MX2024008989A (enExample)
PE (1) PE20250779A1 (enExample)
TW (1) TW202345865A (enExample)
WO (1) WO2023138689A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
KR20240103025A9 (ko) 2021-11-16 2025-12-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
AU2023404700A1 (en) * 2022-12-02 2025-07-10 Shanghai Argo Biopharmaceutical Co., Ltd. Bicyclic abasic nucleic acid analogs and oligomeric compounds prepared therefrom
CN119506275A (zh) * 2023-08-22 2025-02-25 苏州炫景生物科技有限公司 抑制lpa基因表达的双链寡核苷酸及其应用
UY40897A (es) * 2023-09-21 2025-03-31 Ionis Pharmaceuticals Inc Compuestos y métodos para inhibir lpa
WO2025082059A1 (zh) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 经修饰的dsRNA、双链RNAi剂及其用途
CN120344664A (zh) * 2023-10-27 2025-07-18 北京安龙生物医药有限公司 靶向脂蛋白a的寡核苷酸及其用途
CN120020252A (zh) * 2023-11-17 2025-05-20 纳肽得(青岛)生物医药有限公司 抑制LPA表达的siRNA及其用途
CN122514601A (zh) * 2023-11-29 2026-08-04 美国圣因生物股份有限公司 靶向Lp(a)的小干扰RNA及其用途
TW202546233A (zh) * 2024-02-05 2025-12-01 美商靖因藥業（上海）有限公司 用於抑制ｌｐ（ａ）或ａｐｏｃ３之表現的多核酸分子、醫藥組合物及其用途
WO2025252159A1 (zh) * 2024-06-06 2025-12-11 大睿生物医药科技(上海)有限公司 调控LPA表达的dsRNA分子
WO2026026890A1 (zh) * 2024-07-31 2026-02-05 前沿生物药业(南京)股份有限公司 用于抑制LPA基因表达的siRNA及其修饰物与应用
WO2026092650A1 (zh) * 2024-11-01 2026-05-07 迈威(上海)生物科技股份有限公司 一种抑制LPA基因表达的RNAi制剂及其应用
WO2026131490A1 (en) * 2024-12-20 2026-06-25 Ribocure Pharmaceuticals Ab Oligonucleotide, oligonucleotide conjugate and composition, and use thereof
WO2026133253A1 (en) 2024-12-20 2026-06-25 Novartis Ag Combinations of antisense agents, pharmaceutical compositions and methods of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
CA2622583A1 (en) * 2005-09-15 2007-03-22 Henrik Frydenlund Hansen Rna antagonist compounds for the inhibition of apo-b100 expression
CN101292034A (zh) * 2005-09-15 2008-10-22 桑塔里斯制药公司 抑制apo-b100表达的rna拮抗化合物
RU2624028C2 (ru) * 2012-05-24 2017-06-30 Ионис Фармасьютикалз, Инк. Способы и композиции для модулирования экспрессии аполипопротеина (а)
PL2992098T3 (pl) * 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
JOP20170056B1 (ar) * 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
SG11201912178VA (en) * 2017-09-11 2020-01-30 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
EP3483270A1 (en) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
CN119120476A (zh) * 2017-11-13 2024-12-13 赛伦斯治疗有限责任公司 用于抑制细胞中lpa的表达的核酸
AU2019380628B2 (en) * 2018-11-13 2024-10-31 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of LPA in a cell
JP7507495B2 (ja) * 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
EP3923989A1 (en) 2019-03-21 2021-12-22 Mitotherapeutix LLC Multivalent ligand clusters for targeted delivery of therapeutic agents
JP7827623B2 (ja) * 2019-12-09 2026-03-10 アムジエン・インコーポレーテツド ＬＰＡ発現を阻害するためのＲＮＡｉコンストラクト及び方法
EP4229201A1 (en) * 2020-10-16 2023-08-23 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
US20250283076A1 (en) * 2021-09-14 2025-09-11 Argonaute RNA Limited Treatment of cardiovascular disease
WO2023041079A1 (zh) * 2021-09-18 2023-03-23 上海金中锘美生物医药科技有限公司 Lpa抑制剂及其用途
WO2024035898A2 (en) * 2022-08-11 2024-02-15 Sirius Therapeutics, Inc. Polynucleic acid molecules for inhibiting expression of lp(a), pharmaceutical compositions, and uses thereof

Also Published As

Publication number Publication date
KR20240135657A (ko) 2024-09-11
TW202345865A (zh) 2023-12-01
DOP2024000141A (es) 2024-10-15
PE20250779A1 (es) 2025-03-14
EP4471144A4 (en) 2026-01-21
US20250257356A1 (en) 2025-08-14
IL314060A (en) 2024-09-01
JOP20240159A1 (ar) 2024-07-21
JP7833044B2 (ja) 2026-03-18
CL2024002168A1 (es) 2025-01-10
MX2024008989A (es) 2024-07-29
CO2024009492A2 (es) 2024-10-31
EP4471144A1 (en) 2024-12-04
CA3248387A1 (en) 2025-07-09
US20250297250A1 (en) 2025-09-25
WO2023138689A1 (zh) 2023-07-27
AU2023210010A1 (en) 2024-07-25
JP2026116903A (ja) 2026-07-14
JP2025504863A (ja) 2025-02-19

Similar Documents

Publication Publication Date Title
EP4471144A1 (en) Composition and method for inhibiting expression of protein lpa(apo(a))
CN116940682A (zh) 抑制血管紧张素原（agt）蛋白表达的组合物和方法
CN116888263A (zh) 用于抑制血管生成素样3(angptl3)蛋白表达的组合物和方法
EP4592390A1 (en) Specifically modified rnai reagent and composition
CN119487190A (zh) 用于抑制黄嘌呤脱氢酶(xdh)的组合物和方法
EP4442827A1 (en) Composition and method for inhibiting expression of hepatitis b virus (hbv) protein
CN119546763A (zh) 用于抑制补体成分c3蛋白表达的组合物和方法
CN120641110A (zh) 用于抑制诱导细胞死亡的dffa样效应子b(cideb)表达的组合物和方法
CN121399259A (zh) 用于抑制补体因子b(cfb)表达的组合物和方法
CN120457205A (zh) 抑制17β-羟基类固醇脱氢酶13型(HSD17B13)表达的组合物和方法
CN120239747A (zh) 用于抑制含Patatin样磷脂酶结构域蛋白3(PNPLA3)表达的组合物和方法
CN118510894A (zh) 用于抑制前激肽释放酶（pkk）蛋白表达的组合物和方法
HK40116126A (en) Composition and method for inhibiting expression of protein lpa(apo(a))
HK40123923A (en) Compositions and methods for inhibiting expression of cell death inducing dffa like effector b (cideb)
HK40124149A (en) Compositions and methods for inhibiting expression of 17beta-hydroxysteroid dehydrogenase type 13 (hsd17b13)
HK40123263A (en) Specifically modified rnai reagent and composition
HK40121787A (en) Compositions and methods for inhibiting expression of patatin-like phospholipase domain-containing 3 (pnpla3)
HK40096008A (en) Compositions and methods for inhibiting expression of angiopoietin-like 3 (angptl3) protein
HK40117932A (en) Composition and method for inhibiting expression of hepatitis b virus (hbv) protein
OA21711A (en) Composition and method for inhibiting expression of hepatitis B virus (HBV) protein.
HK40115058A (en) Composition and method for inhibiting angiotensinogen (agt) protein expression
CN121488036A (zh) 用于抑制补体成分3(c3)表达的组合物和方法
CN121488037A (zh) 用于抑制pd-l1表达的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40116334

Country of ref document: HK